Thyroid Eye Disease: Navigating Orbital Pathways to New Treatment...

Actions Panel

Thyroid Eye Disease: Navigating Orbital Pathways to New Treatment...

This program is intended for AAO attendees only.

When and where

Date and time


Renaissance Chicago Downtown Hotel 1 West Wacker Drive Grand Ballroom IV-VI; Second Level Chicago, IL 60601

Map and directions

How to get there

About this event

Activity Chair

Raymond S. Douglas, MD, PhD

Professor of Surgery

Division of Ophthalmology

Director, Orbital and Thyroid Eye Disease Program

Cedars-Sinai Medical Center

Los Angeles, CA


Andrea Lora Kossler, MD, FACS

Director, Oculofacial Plastic & Orbital Surgery

Associate Professor of Ophthalmology

Byers Eye Institute at Stanford University School of Medicine

Palo Alto, CA

Jennifer M. Loh, MD

Founder, Loh Ophthalmology Associates

Board Member, Eye Physicians of Florida, LLP

Miami, FL

Prem S. Subramanian, MD, PhD

Professor of Ophthalmology, Neurology, and Neurosurgery

University of Colorado School of Medicine

Vice Chair for Academic Affairs

Division Head, Neuro-Ophthalmology

University of Colorado Sue Anschutz-Rodgers Eye Center

Aurora, CO


Thyroid eye disease (TED) is an autoimmune disorder believed to result from the stimulation of several receptors located in the orbital fibroblasts. It is frequently misdiagnosed, due to both its heterogeneous clinical presentation and a failure on the part of clinicians to understand the relationship between TED and hyperthyroidism. Misdiagnosis can place patients at risk, as management of TED is most effective during the initial, active phase of the disease. However, differential diagnosis can be achieved with the assistance of imaging, and early treatment may limit disfigurement and reduce vision loss. Ophthalmologists should be knowledgeable about the presentation of these patients, which includes patients with dry eye, as well as conventional and new treatment options available for the treatment of patients with TED. In this case-based program, expert faculty will discuss these treatment options, including teprotumumab—the first and only medical agent approved by the US Food and Drug Administration for the treatment of TED. This program will include the unique, audience-engaging, educational gaming platform, A GameOn! Challenge.


6:00 PM

Registration and Dinner

6:30 PM

Introduction and Pretest

Raymond S. Douglas, MD, PhD

6:35 PM

Thyroid Eye Disease: Pathogenesis and Differential Diagnosis

Prem S. Subramanian, MD, PhD

6:45 PM

Case Presentation: Differential Diagnosis

Jennifer M. Loh, MD

6:55 PM

Thyroid Eye Disease Treatment: Navigating Orbital Pathways

Andrea Lora Kossler, MD

7:15 PM

Case Presentation: Treating Thyroid Eye Disease

Raymond S. Douglas, MD, PhD

7:35 PM

GameOn! Challenge

With your host, Raymond S. Douglas, MD, PhD

7:45 PM

Posttest and Question & Answer

8:00 PM


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the pathogenesis of TED, including targets for treatment.

  • Review the clinical presentation of TED, its symptomatology, and optimal methods to differentially diagnosis the condition to aide in early detection and treatment.

  • Examine currently available TED treatments for their efficacy, safety, and ability to restore visual function and appearance.

Target Audience

The intended audience for this activity is ophthalmologists and other health care professionals involved in the management of patients with TED.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.

This activity is not affiliated with the official program of AAO 2022.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity.

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.